A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia.
A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia.
复制标题
阿米替林和萘普生治疗纤维肌痛患者的随机对照试验。
DOI：
10.1002/art.1780291110
复制
发表时间：
1986
影响因子：
--
通讯作者：
Dinerman,H
中科院分区：
文献类型：
--
作者：
Goldenberg,DL;Felson,DT;Dinerman,H
在一项为期6周的双盲试验中，62名纤维肌痛患者被随机分配接受25 mg阿米替林夜间治疗，500 mg萘普生每日两次治疗，阿米替林和萘普生治疗，或安慰剂治疗。阿米替林与所有结局参数的显著改善相关，包括患者和医生的总体评估、患者疼痛、睡眠困难、觉醒时疲劳和压痛点评分。与单独服用阿米替林的患者相比，服用萘普生-阿米替林联合治疗方案的患者疼痛改善较小，但不显著。阿米替林，或阿米替林和萘普生，是一种有效的治疗方案与纤维肌痛患者。
Sixty‐two patients with fibromyalgia were randomly assigned to receive 25 mg of amitriptyline at night, 500 mg of naproxen twice daily, both amitriptyline and naproxen, or placebo in a 6‐week, double‐blind trial. Amitriptyline was associated with significant improvement in all outcome parameters, including patient and physician global assessments, patient pain, sleep difficulties, fatigue on awakening, and tender point score. Patients taking the combined naproxen—amitriptyline regimen experienced minor, but not significant, improvement in pain when compared with patients who took amitriptyline alone. Amitriptyline, or amitriptyline and naproxen, is an effective therapeutic regimen for patients with fibromyalgia.